Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Stz4.2

Stanozolol (Winstrol) – Forschung

Überwiegend Mechanismus / Beobachtung

19 begutachtete Studien

Was die Evidenz sagt

Überwiegend Mechanismus / Beobachtung

Die meisten Studien zu Stanozolol (Winstrol) sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.

Die meiste Evidenz stammt aus hochwertigen randomisierten Studien, veröffentlicht 1972–2017 mit einer typischen Studiengröße von 11 Teilnehmenden.

Basierend auf 19 Studien · 14 RCTs · 11 Teilnehmende insgesamt

Konfidenz

Mittlere Konfidenz

Nach Outcome

Hereditary angioedema
Überwiegend Mechanismus / Beobachtung3 Studien
Liver & hepatotoxicity
Überwiegend Mechanismus / Beobachtung3 Studien
Lean mass & anabolic effectEin anaboles androgenes Steroid (Winstrol), das bei nichtmedizinischer Anwendung Magermasse/Kraft aufbaut, jedoch einen schweren HDL-Abfall, Hepatotoxizität, HPTA-Suppression und Sehnenrisiko verursacht. Eine kontrollierte Substanz (medizinisch nur für hereditäres Angioödem zugelassen). · Für den Einsatz zur Körperformung nicht etabliert
Überwiegend Mechanismus / Beobachtung3 Studien
Safety profile
Zu wenige bewertete Studien2 Studien
Cholesterol & the HDL crash
Zu wenige bewertete Studien1 Studie

Ältere Forschungsbasis

Neueste Studie von 2017

197219942017

1Systematische Übersicht2015

Riedl MA · Ann Allergy Asthma Immunol (2015)

Quelle ansehen

2RCT1998

Yuan A, Liu C, Huang X · Zhongguo Zhong Xi Yi Jie He Za Zhi (1998)

3RCT2015

Carson P, Hong CJ, Otero-Vinas M, Arsenault EF, Falanga V · Int J Low Extrem Wounds (2015)

Quelle ansehen

4RCT1986

Beringer TR, Ardill J, Taggart HM · Bone Miner (1986)

5RCT1981

Mandelli F, Amadori S, Dini E, Grignani F, Leoni P, Liso V · Leuk Res (1981)

Quelle ansehen

6RCT1991

Berridge DC, Frier M, Westby JC, Hopkinson BR, Makin GS · Br J Surg (1991)

Quelle ansehen

7RCT1985

Cuschieri RJ, Morran CG, Lowe GD, Blamey SL, Forbes CD, McArdle CS · Haemostasis (1985)

Quelle ansehen

8RCT1989

Hansell DT, Davies JW, Shenkin A, Garden OJ, Burns HJ, Carter DC · JPEN J Parenter Enteral Nutr (1989)

Quelle ansehen

9RCT1991

Jayson MI, Holland CD, Keegan A, Illingworth K, Taylor L · Ann Rheum Dis (1991)

Quelle ansehen

10RCT1972

Davidson JF, Lochhead M, McDonald GA, McNicol GP · Br J Haematol (1972)

11RCT1991

McMullin GM, Watkin GT, Coleridge Smith PD, Scurr JH · Aust N Z J Surg (1991)

Quelle ansehen

12RCT1980

Burnand K, Clemenson G, Morland M, Jarrett PE, Browse NL · Br Med J (1980)

Quelle ansehen

13RCT2001

Parsad D, Pandhi R, Juneja A · J Dermatol (2001)

Quelle ansehen

14RCT1986

Belch JJ, Madhok R, McArdle B, McLaughlin K, Kluft C, Forbes CD · Q J Med (1986)

15Crossovern=11 · very small study1989

Einfach gesagt: Stanozolol reduced HDL-cholesterol and the HDL2 subfraction by 33% and 71%, respectively. ... Apolipoprotein A-I level decreased 40% during stanozolol ... The low-density lipoprotein cholesterol concentration increased 29% with stanozolol.

Thompson PD, Cullinane EM, Sady SP, Chenevert C, Saritelli AL · JAMA (1989)

The headline counter-evidence on lipids: a randomized crossover trial in 11 male weight-lifters comparing oral stanozolol 6 mg/day with supraphysiological intramuscular testosterone enanthate over six weeks
Oral stanozolol cut HDL cholesterol by 33%, the cardioprotective HDL2 subfraction by 71% and apolipoprotein A-I by 40%, while raising LDL cholesterol by 29% — one of the most dramatic lipid derangements documented for any drug
The effect dwarfed that of supraphysiological IM testosterone in the same men, isolating the harm to the oral 17α-alkylated route rather than androgenicity per se

16Übersicht2017

Einfach gesagt: Relevant concern has been raised by the AAS hepatotoxicity including adenoma, hepatocellular carcinoma, cholestasis, and peliosis hepatis.

Solimini R, Rotolo MC, Mastrobattista L, Mortali C, Minutillo A, Pichini S, Pacifici R, Palmi I · European review for medical and pharmacological sciences (2017)

Mandatory class-level counter-evidence on non-medical use: a review of the hepatotoxic effects of anabolic-androgenic steroids in doping and general-population misuse
AAS hepatotoxicity spans hepatic adenoma, hepatocellular carcinoma, cholestasis and peliosis hepatis — the severe end of the liver-injury spectrum
Notes AAS are frequently present in over-the-counter 'dietary supplements' without label declaration, leaving consumers unaware of the risk

17Beobachtungsstudie2007

Einfach gesagt: The minimal initial effective dosage of stanozolol was 0.5 to 2.0 mg daily, although most patients achieved symptomatic control and decreased the dose and frequency as the frequency of attacks decreased.

Sloane DE, Lee CW, Sheffer AL · The Journal of allergy and clinical immunology (2007)

Outcome anchor for the approved indication: a cohort of hereditary-angioedema patients treated with stanozolol for 20 to 40 years at a single institution
Documents durable attack control at low maintenance doses (initial 0.5–2.0 mg/day, often reduced further over time)
Long follow-up also surfaces the long-term harms — patients were monitored with hepatic-function assays, serum lipids, PSA and liver ultrasound, with treatment-related symptoms reported

Quelle ansehen

18Übersicht2008

Einfach gesagt: Attenuated androgens have been successful in the short- and long-term treatment of HAE ... Scheduled monitoring of liver function tests and lipid profiles in patients treated with these medications is critical.

Banerji A, Sloane DE, Sheffer AL · Annals of allergy, asthma & immunology (2008)

State-of-the-art review of 40–50 years of attenuated-androgen use (including stanozolol) for hereditary angioedema
Confirms successful short- and long-term treatment of HAE — the clinical consensus underpinning the approved indication
States that scheduled monitoring of liver-function tests and lipid profiles is critical, and that use in children and pregnant women must be undertaken with great caution

Quelle ansehen

19Tierstudie1992

Einfach gesagt: The results of the biomechanical tests suggested that anabolic steroids produce a stiffer tendon, which fails with less elongation. ... Alterations of the sizes of the collagen fibrils were noted on electron microscopy.

Miles JW, Grana WA, Egle D, Min KW, Chitwood J · The Journal of bone and joint surgery. American volume (1992)

Mechanistic animal evidence for the connective-tissue concern: 24 rats randomized across anabolic-steroid and exercise variables, with biomechanical and histological tendon testing
Anabolic steroids produced a stiffer tendon that failed with less elongation, with altered collagen-fibril sizes on electron microscopy
Offers a biological basis for the tendon- and ligament-rupture reports in athletes who use anabolic steroids

In der Forschungsbibliothek ansehen

Stanozolol (Winstrol) – Forschung

Überwiegend Mechanismus / Beobachtung

Critical appraisal of androgen use in hereditary angioedema: a systematic review.

[Treatment of 34 cases of chronic aplastic anemia using prepared Rehmannia polysaccharide associated with stanozolol].

Liver enzymes and lipid levels in patients with lipodermatosclerosis and venous ulcers treated with a prototypic anabolic steroid (stanozolol): a prospective, randomized, double-blinded, placebo-controlled trial.

Effect of calcium and stanozolol on calcitonin secretion in patients with femoral neck fracture.

Randomized clinical trial of immunotherapy and androgenotherapy for remission maintenance in acute non-lymphocytic leukemia.

Double-blind randomized trial of perioperative fibrinolytic enhancement for femoropopliteal bypass.

The effect of fibrinolytic stimulation by stanozolol on postoperative pulmonary complications.

The effects of an anabolic steroid and peripherally administered intravenous nutrition in the early postoperative period.

A controlled study of stanozolol in primary Raynaud's phenomenon and systemic sclerosis.

Fibrinolytic enhancement by stanozolol: a double blind trial.

Efficacy of fibrinolytic enhancement with stanozolol in the treatment of venous insufficiency.

Venous lipodermatosclerosis: treatment by fibrinolytic enhancement and elastic compression.

Stanozolol in chronic urticaria: a double blind, placebo controlled trial.

The effect of increasing fibrinolysis in patients with rheumatoid arthritis: a double blind study of stanozolol.

Contrasting effects of testosterone and stanozolol on serum lipoprotein levels.

Hepatotoxicity associated with illicit use of anabolic androgenic steroids in doping.

Hereditary angioedema: Safety of long-term stanozolol therapy.

Hereditary angioedema: a current state-of-the-art review, V: attenuated androgens for the treatment of hereditary angioedema.

The effect of anabolic steroids on the biomechanical and histological properties of rat tendon.